Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
Holding SAGE?
Track your performance easily
SAGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.19 - $28.26
Previous Close$7.52
Volume652.94K
Average Volume (3M)874.34K
Market Cap
$459.10M
Enterprise Value-$186.28M
Total Cash (Recent Filing)$646.79M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 05, 2024EPS Estimate
-$1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.41
Shares Outstanding61,050,418
10 Day Avg. Volume546,358
30 Day Avg. Volume874,342
Standard Deviation0.16
R-Squared0.08
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.74
Price to Sales (P/S)4.72
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-10.88
Enterprise Value/Gross Profit-2.15
Enterprise Value/Ebitda0.31
Forecast
1Y Price Target
$12.47Price Target Upside64.30% Upside
Rating ConsensusHold
Number of Analyst Covering17
SAGE Therapeutics News
Bulls Say, Bears Say
Bulls Say
Positive Market ResponseZurzuvae shows progress with OB/GYNs leading the script writing, which bodes well for future growth.
Prescription GrowthZurzuvae sales were modestly above consensus, and there is encouragement from the strong prescription growth and significant commercial and Medicaid coverage expansion.
Salesforce ExpansionStrategic expansion of the Zurzuvae sales force planned for early 4Q24.
Bears Say
Clinical TrialsThe failure of KINETIC-2 likely weakens the overall collaboration with Biogen and could increase the risk on the Zurzuvae partnership.
Financial OutlookThe price target is lowered primarily due to higher spending assumptions.
Sales PerformanceZurzuvae sales were below forecast due to wholesaler destocking and free drugs, with potential for more destocking.
---
Ownership Overview
7.85% Insiders
34.80% Mutual Funds
45.85% Other Institutional Investors
11.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $7.19 and its highest was $28.26 in the past 12 months.
What is SAGE Therapeutics’s market cap?
Currently, no data Available
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is Nov 05, 2024 which is in 47 days.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on Jul 31, 2024. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$1.641 by -$0.059.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate is -$1.55.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 61,050,420 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$1.7 in its last earnings report, missing expectations of -$1.641. Following the earnings report the stock price went up 1.389%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Among the largest hedge funds holding SAGE Therapeutics’s share is Fisher Asset Management LLC. It holds SAGE Therapeutics’s shares valued at 5M.
---
SAGE Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.47 (64.30% Upside)
$12.47 (64.30% Upside)
Blogger Sentiment
Bullish
SAGE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 618.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.22%
12-Months-Change
Fundamentals
Return on Equity
-55.28%
Trailing 12-Months
Asset Growth
-35.59%
Trailing 12-Months
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
SAGE Company Deck
---
SAGE Earnings Call
Q2 2024
0:00 / 0:00
---
SAGE Stock 12 Month Forecast
Average Price Target
$12.47
▲(64.30% Upside)
Technical Analysis
Best Analysts Covering SAGE
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
-1.29%
reiterated a sell rating 3 months ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -1.29% per trade.
---